Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spyre TherapeuticsSYRE -1.17%26 3-Year EBITDA Growth Rate is 48.10% as of Jun. 2026, which is 128% above its 10-year median of 21.10. GuruFocus rates SYRE with a GF Score™ of 26/100. The stock has 3 warning signs investors should review. Among 1,127 Biotechnology companies, Spyre Therapeutics ranks better than 84.56% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 48.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 39.10% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 20.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Spyre Therapeutics was 48.10% per year. The lowest was -30.20% per year. And the median was 21.10% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Spyre Therapeutics 3-Year EBITDA Growth Rate Related Terms
SYRE vs TGTX, IMVT, IBRX: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Spyre Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spyre Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Spyre Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 48.10% mean?
Spyre Therapeutics (SYRE) has a 3-Year EBITDA Growth Rate of 48.10% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Spyre Therapeutics and its competitors. This is 128% above median its historical median of 21.10. According to the industry distribution chart, Spyre Therapeutics ranks #174 out of 1127 companies in the Biotechnology industry, placing it in the top 15.4%.
Is Spyre Therapeutics' 3-Year EBITDA Growth Rate too high?
Spyre Therapeutics' current 3-Year EBITDA Growth Rate of 48.10% is 128% above median its 10-year median of 21.10. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Spyre Therapeutics' value of 48.10% is 222.8% above this industry median. Based on the distribution chart, Spyre Therapeutics ranks #174 out of 1127 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Spyre Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Spyre Therapeutics' 3-Year EBITDA Growth Rate compare to TGTX and IMVT?
According to the Biotechnology industry distribution chart, Spyre Therapeutics ranks #174 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Spyre Therapeutics in the top 15% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.90. Spyre Therapeutics' value of 48.10% is 222.8% above this benchmark. While the company's 10-year median is 21.10 vs. the industry median of 14.90, Spyre Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spyre Therapeutics's current 3-Year EBITDA Growth Rate of 48.10% is 222.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Spyre Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spyre Therapeutics's current 3-Year EBITDA Growth Rate is 48.10%, which is 128% above median its own 10-year median of 21.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spyre Therapeutics stock overvalued right now?
Spyre Therapeutics (SYRE) has a current 3-Year EBITDA Growth Rate of 48.10%. The current 3-Year EBITDA Growth Rate is 48.10%, which is 128% above median its 10-year median of 21.10 and 222.8% above the Biotechnology industry median of 14.90. Spyre Therapeutics' overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Spyre Therapeutics (SYRE), the current 3-Year EBITDA Growth Rate is 48.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
26GF Score
Get the complete analysis for SYRE
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SYRE has been successfully added to your 
